ReviewOncotarget2016
Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions.
Review in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 55 citations in OpenAlex.
- Fibrinogen-Drug Nanoparticles Achieve Durable Responses in Pancreatic and Breast Cancer Murine Models.ACS pharmacology & translational science · 2026Article
- Vascular Disruption Therapy as a New Strategy for Cancer Treatment.International journal of molecular sciences · 2025Review
- Evaluating Immune Activation Feasibility in Pancreatic Ductal Adenocarcinoma via Oxygen Bubble-Induced Anti-Vascular Therapy.Pharmaceutics · 2025Article
- Nanotechnology-based biomedical devices in the cancer diagnostics and therapy.Medical oncology (Northwood, London, England) · 2025Review
- Combination of vascular surgery with novel vascular targeting agents as cancer therapeutics.Frontiers in oncology · 2025Review
- Targeting the tumour vasculature: from vessel destruction to promotion.Nature reviews. Cancer · 2024Review
- Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy.Scientific reports · 2024Article
- Advances of medical nanorobots for future cancer treatments.Journal of hematology & oncology · 2023Review
- Challenges and Opportunities Associated With Drug Delivery for the Treatment of Solid Tumors.Oncology reviews · 2023Review
- Article
- [An injectable hydrogel/staple fiber composite for sustained release of CA4P and doxorubicin for combined chemotherapy of xenografted breast tumor in mice].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Recent advances of nanotechnology-based tumor vessel-targeting strategies.Journal of nanobiotechnology · 2021Review
- Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression.Scientific reports · 2021Article
- Article
- Article
- Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.Molecules (Basel, Switzerland) · 2021Review
- Article
- MnOAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate.Scientific reports · 2020Article
- Photochemically-Induced Release of Lysosomal Sequestered Sunitinib: Obstacles for Therapeutic Efficacy.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of vascular disrupting agents (VDAs) is a significant advance in the treatment of solid tumors. VDAs induce rapid and selective shutdown of tumor blood flow resulting in massive necrosis. However, a viable marginal tumor rim always remains after VDA treatment and is a major cause of recurrence. In this review, we discuss the mechanisms involved in the resistance of solid tumors to VDAs. Hypoxia, tumor-associated macrophages, and bone marrow-derived circulating endothelial progenitor cells all may contribute to resistance. Resistance can be monitored using magnetic resonance imaging markers. The various solutions proposed to manage tumor resistance to VDAs emphasize combining these agents with other approaches including antiangiogenic agents, chemotherapy, radiotherapy, radioimmunotherapy, and sequential dual-targeting internal radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.